Verition Fund Management
TCRT icon

Verition Fund Management’s Alaunos Therapeutics TCRT Stock Holding History

Verition Fund Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-162
Closed -$42K – 2717
2022
Q3 		$42K Hold
162
– – ﹤0.01% 2708
2022
Q2 		$30K Buy
+162
New +$15.5K ﹤0.01% 2190
2014
Q1 		– Sell
-68
Closed -$44K – 641
2013
Q4 		$44K Buy
+68
New +$40.5K 0.01% 481

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Verition Fund Management's TCRT Position: Q4 2022 in Review

Verition Fund Management sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 162 shares — an estimated $42K sold.

Verition Fund Management first reported a position in TCRT in Q4 2013 and held it in 3 quarters. The position peaked at $44K in Q4 2013. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Verition Fund Management reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Verition Fund Management sold 162 Alaunos Therapeutics shares in Q4 2022, an estimated $42K.
  • Verition Fund Management first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 3 quarters.
  • Verition Fund Management's Alaunos Therapeutics position peaked at $44K in Q4 2013.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.